Shares of biotech company Oncothyreon (NASDAQ: ONTY) fell more than 50% yesterday. The company released Phase 3 data for its drug Stimuvax, an experimental vaccine that treats non-small cell lung cancer, which showed that the drug failed to improve overall survival for patients in the clinical trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn take us through the details.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.